Aleniglipron Hepatic Impairment Study
A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Aleniglipron Pharmacokinetics
The purpose of this study is to evaluate the PK of aleniglipron in participants with Hepatic Impairment to establish scientifically guided dosing recommendations in these special patient populations.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Medical Director
- Telefonnummer: 650-457-1959
- E-mail: GSBRClinicalTrials@Structuretx.com
Studiesteder
-
-
Florida
-
Orlando, Florida, Forenede Stater, 32809
- Rekruttering
- Research Site
-
Kontakt:
- Medical Director
- Telefonnummer: 650-457-1959
- E-mail: GSBRClinicalTrials@Structuretx.com
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78215
- Rekruttering
- Research Site
-
Kontakt:
- Medical Director
- Telefonnummer: 650-457-1959
- E-mail: GSBRClinicalTrials@Structuretx.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Is an adult, male or female, ≥ 18 to 85 years of age (inclusive), at screening.
- Female and male participants must follow protocol-specified contraception guidance as described in Section 5.4.2.1 and Section 5.4.2.2.
- Is a continuous non-smoker or smoker (≤ 10 cigarettes per day or equivalent) for at least 3 months prior to dosing. Participants must agree to maintain the same smoking status (i.e., smoker or non-smoker) from screening and until after the last PK sample collection.
- BMI ≥ 17.0 and ≤ 40.0 kg/m2 and weight of at least 40.0 kg at screening.
- Understands the study procedures in the ICF and be willing and able to comply with the protocol and communicate effectively with study personnel.
Exclusion Criteria:
- Is mentally or legally incapacitated or has significant emotional problems at the time of screening or expected during the conduct of the study.
- History or presence of alcohol or drug abuse (including participants with symptoms of cannabis disorder) within the past 6 months prior to the dosing.
- History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
- Female participant with a positive serum pregnancy test at screening or at check-in or who is lactating or breastfeeding.
- Has positive drug results at screening or at check-in, unless the positive drug screen is due to prescription drug use that is approved by the PI or designee. Participants with a positive result for cannabinoids may be enrolled at the discretion of the PI or designee and the Sponsor.
- Has taken medications intended to promote weight loss within 3 months or 5 half-lives, whichever is longer, prior to screening, including, but not limited to GLP-1 RAs.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Participants will receive aleniglipron administered orally Part 1
Aleniglipron administered orally. |
administered orally |
|
Eksperimentel: Participants will receive aleniglipron administered orally Part 2
Aleniglipron administered orally. |
administered orally |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
PK parameters including but not limited to AUC0-t
Tidsramme: Baseline to Day 5 (Part 1)
|
Baseline to Day 5 (Part 1)
|
|
PK parameters including but not limited to AUC0-inf
Tidsramme: Baseline to Day 5 (Part 1)
|
Baseline to Day 5 (Part 1)
|
|
PK parameters including but not limited to Cmax
Tidsramme: Baseline to Day 5 (Part 1)
|
Baseline to Day 5 (Part 1)
|
|
PK parameters including but not limited to AUC0-t
Tidsramme: Baseline to Day 5 (Part 2)
|
Baseline to Day 5 (Part 2)
|
|
PK parameters including but not limited to AUC0-inf
Tidsramme: Baseline to Day 5 (Part 2)
|
Baseline to Day 5 (Part 2)
|
|
PK parameters including but not limited to Cmax
Tidsramme: Baseline to Day 5 (Part 2)
|
Baseline to Day 5 (Part 2)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- GSBR-1290-20
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .